Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09
Thu Feb 05 2026
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56.
Key topics included:
• The design and findings of the DESTINY-Breast09 trial
• Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane)
• The implications of these findings for clinical practice
• The role of maintenance therapy and the potential for personalized treatment strategies
• Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease)
Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!
#HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers
More
In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56. Key topics included: • The design and findings of the DESTINY-Breast09 trial • Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane) • The implications of these findings for clinical practice • The role of maintenance therapy and the potential for personalized treatment strategies • Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease) Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers